Verneuil's disease is a chronic, suppurative dermatosis involving the apocrine glands with a severe impact on the quality of life.
There is no standard treatment for this disease, and the drugs usually prescribed are often poorly effective. Therefore, a new therapeutic approach based on zinc salts was investigated with 22 patients, mainly from grade I or II in Hurley’s clinical staging.
All patients included had previously been prescribed a treatment (antibiotic, isotretinoin, surgery or anti-androgens), which was inefficient. The patients were treated with 90 mg of zinc gluconate per day (15 mg zinc, 6 times per day).
A clinical response in all patients was observed, with 8 complete remissions and 14 partial remissions. When complete remission was obtained, the treatment was progressively decreased; however, relapses occurred when reaching 2-4 capsules per day, depending on the severity of the disease. Recurrence disappeared when the dosage was increased again, suggesting that the treatment is suppressive rather than curative.
The treatment was well tolerated (4/22 patients experiencing side-effects, mainly gastro-intestinal), and this is crucial in the context of a chronic disease strongly affecting quality of life.
Carla Holmes | Source: alphagalileo
Further information: www.karger.com
More articles from Studies and Analyses:
'Too fat to be a princess?' UCF study shows young girls worry about body image
25.11.2009 | University of Central Florida
Eye floaters and flashes of light linked to retinal tear, detachment
25.11.2009 | Queen's University
First black holes may have incubated in giant, starlike cocoons
25.11.2009 | Physics and Astronomy
KfW issues its first ever 7 year Euro-Benchmark
25.11.2009 | Business and Finance
Intelligence inside metal components
25.11.2009 | Information Technology
Multidisciplinary meeting on Urological Cancers aims to benefit cancer patients
20.11.2009 | Event News
'Golden Age' for clinical psychology in Northern Ireland
20.11.2009 | Event News
New Perspectives in Marine Anti-Fouling Research
11.11.2009 | Event News